PrecisionLife and Nxera Pharma have expanded their collaborative partnership to potentially discover new drug targets for treating auto-immune disorders. The collaboration was announced as an extension of the companies' existing partnership, established in 2022.

The partnership aims to establish precision-targeted therapies for auto-immune disorders. PrecisionLife's disease insights and stratification biomarkers will be used to identify patient subgroups, enabling Nxera to determine suitable drug targets accurately. This collaboration aims to leverage the combined strengths of both companies to develop effective treatments for complex diseases in the future.

UK-based PrecisionLife specializes in generating biological insights into complex chronic diseases. Leveraging its AI-led Innovation Engine and combinatorial analytics, the company aims to accelerate drug development and personalize healthcare by identifying disease mechanisms relevant to specific patients. The company’s services include discovering novel drug targets, enriching clinical trials, and creating personalized diagnostics.